Early reduction of left atrial function predicts adverse clinical outcomes in patients with severe aortic stenosis undergoing transcatheter aortic valve replacement.

AIMS: To investigate the changes in left atrial strain (LAS) after correction of severe aortic stenosis (AS) with transcatheter aortic valve replacement (TAVR) and assess its prognostic impact. METHODS AND
RESULTS: One hundred consecutive patients with severe symptomatic AS who underwent TAVR at the Magna Graecia University of Catanzaro underwent echocardiographic examination including assessment of LAS before and after TAVR. Independent investigators collected outcome data and information. The primary study outcome was the difference in ΔLAS (postTAVR-preTAVR) between patients those met the main clinical endpoint (a composite of cardiovascular mortality and heart failure hospitalisation) and those not meeting the endpoint.During a median follow-up of 31 months, 35 patients (35%) met the combined clinical endpoint. The difference between LAS post-TAVR and LAS pre-TAVR (ΔLAS) was significantly larger in patients who met the combined endpoint (HR=0.76 (0.67-0.86); p<0.001). Multivariate logistic regression analysis including ΔLAS, EuroSCORE II and left ventricular ejection fraction showed that ΔLAS (HR=0.80, p<0.001) was the only independent predictor of the combined clinical endpoint. Finally, a Kaplan-Maier analysis showed that patients with a ΔLAS above its median value had a significantly better event-free survival compared with those below the median (p<0.001).
CONCLUSIONS: A lower reduction in ΔLAS after TAVR was an independent predictor of the primary composite outcome of cardiovascular death and hospitalisation for heart failure. © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Successful removal of left ventricular pressure afterload has been revealed to normalise left atrial size.

Left atrial strain (LAS) is emerging as a more precise and reliable index of atrial function.

Improvement in LAS after transcatheter aortic valve replacement (TAVR) is an independent predictor of adverse clinical outcomes.

If confirmed in larger studies, our results pave the way to the use of LAS and its change after TAVR as a clinical biomarker to guide the clinical management of these patients.

Background

Left ventricular (LV) systolic function is a known prognostic marker in cardiovascular disease.1 2 Much less evidence is available about the role of left atrial (LA) function, despite some studies showed how an early functional impairment is often evident before LA dilatation becomes manifest.3–5

The left atrium has a key role in modulating LV filling through its functions of reservoir, conduit and booster pump.6 Several studies have demonstrated the capacity of two-dimensional (2D) speckle-tracking echocardiography (STE) to assess left atrial function in adult patients and in children.7–14

Recently, 2D LA strain has been proposed to accurately categorise diastolic function in adults.15 Furthermore, it has been observed that LA function is associated with adverse long-term outcomes in different cardiomyopathies as well as in patients with aortic stenosis (AS).16–21 Treatment of degenerative AS has become increasingly challenging with the constant increase in mean age at diagnosis.22 Transcatheter aortic valve replacement (TAVR), in the last decade, has emerged as a promising alternative to surgical aortic valve replacement (AVR) for selected patients. To the best of our knowledge, no data are available to date on the prognostic value of LA strain (LAS) measured by means of 2D STE after TAVR.

We investigated the change in LAS in patients with severe AS undergoing TAVR and its prognostic.

Methods

Consecutive patients with severe symptomatic AS who underwent TAVR at the Magna Graecia University of Catanzaro from December 2016 to February 2020 were screened. The echocardiographic examinations were carried out as part of routine clinical care. Patients were included if echocardiographic movie clips, before and after the procedure (pre-TAVR and post-TAVR), were available for LA 2D STE analysis, in addition to conventional echo-Doppler parameters. Exclusion criteria were appointed as follows: presence of a pacemaker, concomitant clinically relevant valvular disease (at least moderate stenosis or valvular regurgitation, n=5), atrial fibrillation at the time of the examination (n=3), poor echogenicity or poor image quality (n=3).

Demographic and laboratory data, comorbidities, as well as functional status, were assessed in all patients. Patients were followed up for the occurrence of adverse events by means of clinical visits.

The investigation conforms with the principles outlined in the Declaration of Helsinki. All patients gave informed consent to the study.

Transthoracic Doppler echocardiography

Standard echocardiography

Transthoracic echocardiographic examinations were performed by using a commercially available ultrasound system (Vivid E95 system, General Electric, Horton, Norway) equipped with a M5S adult transducer, according to the standardised protocol of the Magna Graecia University of Catanzaro.23 Raw data were transferred to a commercially available workstation (EchoPAC V.112.99, Research Release, GE Healthcare) and analysed offline.

The continuity equation was used to measure aortic valve area, according to current guidelines,24 and indexed to body surface area. The peak aortic jet velocity was assessed with continuous-wave Doppler from multiple acoustic views and transaortic mean pressure gradient was obtained according to the Bernoulli equation.

The time-velocity integral of the LV outflow tract (LVOT) was calculated in apical five-chamber view. Stroke volume was determined with LVOT area estimated from the parasternal long-axis view in systole, at the base of the valve leaflets.25

Chamber size and function were assessed as previously described according to the latest guidelines.26 Values for LV diameters and volumes were adjusted for body surface area (BSA).26 Left ventricular ejection fraction (LVEF) was calculated according to the modified Simpson’s rule, while left ventricular mass index was adjusted according to the formula of the American Society of Echocardiography.

The following standard parameters were measured by one expert cardiologist, according to the latest guidelines27: mitral inflow early-to-late diastolic flow ratio, mitral lateral and septal peak early diastolic tissue velocities, mitral E-to-mean E’ ratio (E/E’). Moreover, left atrial volume indexed (LAVi) to BSA was derived from the apical four chamber view. The change in LAVi after TAVR compared with baseline was calculated as the delta value (ΔLAVi).

The maximum tricuspid regurgitation velocity was used to estimate the peak tricuspid regurgitation gradient by means of the modified Bernoulli equation. The pulmonary artery systolic pressure (PASP) was measured from this by adding right atrial pressure (estimated by looking at diameter and respiratory variation of inferior vena cava).

Two-dimensional speckle-tracking analysis

Two-dimensional STE analyses were performed by a different experienced cardiologist, using EchoPAC software.

For speckle-tracking analysis, apical four-chamber views images were acquired, using standard 2D grey scale echocardiography, during breath hold and with a stable ECG recording.14 23

To assure optimal tracking, three consecutive heart cycles were collected at a frame rate of 50–80 frames/s, sinus rhythm and ≤10% variability in heart rate.14 23

As depicted in figure 1, the LA endocardial border was traced excluding appendage and pulmonary veins from the LA cavity, from the apical four-chamber view. Hence, LA longitudinal strain and strain rate curves were created from the software throughout the cardiac cycle. The LA wall longitudinal lengthening during the LV systole was measured and employed for the analysis (LA peak systolic strain, LAS).14 The change in LAS after TAVR compared with baseline was calculated as the delta value (ΔLAS).

Figure 1

How to assess left atrial strain. Acquire a four-chamber apical view (A). Adjust the image sector in order to focus on the left atrium (B). After recording the images (from three to five cycles) select on the EchoPAC offline platform the Q analysis option. Trace the atrial border (C). Approve and process the curve analysis, generating the peak atrial longitudinal strain (PALS, white arrow, D) and strain rate (left atrial peak strain rate S-wave (LASRs); left atrial strain rate E-wave (LASRe); left atrial strain rate A-wave (LASRa)).

TAVR

TAVR was carried out in all population in accordance with standard technique.20 A transfemoral vascular access was adopted in all patients. Both self-expandable and balloon-expandable prosthetic valves were employed.

Follow-up

Two independent investigators, blinded to the analyses results, collected outcome data and information.

Clinical data were acquired in all population through telephone contact with the patients, with the referring physician or through an outpatient medical visit. Hospital records were employed to corroborate outcomes.

The main clinical endpoint was the composite of cardiovascular-mortality and heart failure hospitalisation. Secondary endpoints included: death for any cause, new myocardial infarction and stroke/transient ischaemic attack.

AS patients were divided in two comparative groups, those who meet the primary endpoint (cardiovascular death or hospitalisation for heart failure) were labelled as ‘EVENTS’, while all others as ‘NO EVENTS’.

Reproducibility study

Interobserver variability for atrial deformation properties was assessed in 20 randomly selected examinations and was calculated as the ratio (indicated as a percentage) of the difference between the measures obtained by each investigator (indicated as an absolute value) divided by the mean of the two measures, and as intraclass correlation coefficients. Intraobserver variability was assessed by a similar approach.

Statistical analysis

Statistical analyses were performed using JASP (V.0.14.1) and KMWin (V.1.52). Distribution of variables was judged by visual inspection of frequency histograms, and normality was proven using the Shapiro-Wilk test. Continuous variables were presented as mean and SD and were compared through the unpaired Student’s t-test or the Mann-Whitney U test in case of a non-normal distribution. Differences between categorical variables were tested with the χ2 test. Multiple logistic regression analysis was performed to identify independent correlates of ΔLAS and to calculate HR with 95% CI. Patient survival curves for the absence of adverse events (cardiovascular-mortality or heart failure hospitalisation) were constructed according to the Kaplan-Meier method and compared by the log-rank test. Sensitivity analysis was conducted using subgroup analysis and the leave-one-out approach. The statistical significance was defined as two-sided p value<0.05.

Sample size calculation. Based on previous literature, we estimated a mean LAS of 15% in the study population and hypothesised a 20%–25% reduction after TAVR. From previous literature, we expected that 30%–35% of study patients would have met the main clinical (composite) endpoint. Thus, we calculated that 96 patients would have been required to detect a 20% difference in ΔLAS between the two groups with a 90% power and an alpha level of 0.005. However, the sample size was adjusted to 100 patients to account for patients/data lost.

Results

The baseline characteristics of the study population are summarised in tables 1 and 2. Mean aortic valve area was 0.75±0.15 cm². Ten patients presented with low-flow low-gradient AS patients (aortic valve area 0.73±0.14 cm²), having a lower baseline mean gradient (26.2±3.8 mm Hg, p<0.001) and a lower LVEF (36.9%±6.7%, p<0.001) compared with the remaining patients with classical high-gradient normal flow AS (table 3).

Table 3

Characteristics of patient with low flow/low gradient AS

	Low-flow, low-gradient AS	Normal-flow, high-gradient	Significance(p value)
	n=10	n=90
AVA baseline (cm2)	0.73±0.14	0.76±0.15	0.571
AV mean gradient baseline (mm Hg)	26.2±3.8	50.3±11.7	<0.001
PASP baseline (mm Hg)	39.3±12.7%	39.5±11.8%	0.966
LVEF baseline (%)	36.9±6.7	55.4±7.3	<0.001
LVEDD baseline (mm)	55.3±9.1	49.8±5.4	0.006
LVESD baseline (mm)	43.8±10.7	32.6±6	<0.001
IVSd (mm)	11.6±1.3	13.1±1.6	0.006
TAPSE baseline (mm)	18.8±2.4	22±2.6	0.005
E/A	0.8±0.6	0.7±0.3	0.501
E/E‘ average	15±6	13.5±2.8	0.234
EuroSCORE II baseline (%)	12.0±13.4	5.1±3.4	<0.001
LAS, pre-TAVR	10.6±4.8	15.6±5.9	0.011
ΔLAS	−1.08±4.46%	0.36±4.95%	0.407
LAVi, pre-TAVR (mL/m2)	49.7±22.5	48.1±13.1	0.791
ΔLAVi	−8.1±15.7	−11.6±17.4	0.672

AS, aortic stenosis; AV, aortic valve; AVA, aortic valve area; E/A, early-to-late diastolic flow ratio; E/E’, E-to-mean E’ ratio; IVSd, interventricular septal diameter diastolic; LAS, left atrial strain; LAVi, left atrial volume index; LVEDD, left ventricular end-diastolic diameter; LVEF, left ventricular ejection fraction; LVESD, left ventricular end-systolic diameter; PASP, pulmonary artery systolic pressure; TAPSE, tricuspid annular plane excursion; TAVR, transcatheter aortic valve replacement.

Of the patients included in the study, 48 out of 100 had concomitant mild aortic regurgitation (AR), while 34 out 100 had mild-to-moderate AR. Mean baseline LAVi and LAS were 48.1±13.8 mL/m2 and 15.3%±5.9%, respectively. Ninety per cent of the study population had concomitant arterial hypertension, 91% were in class NYHA III and nearly one-third presented with diabetes mellitus (table 2). All patients were on optimal medical treatment.

Table 2

Baseline and procedural characteristics (n=100)

Hypertension, n (%)	90 (90)
Smoking, n (%)	16 (16)
Dyslipidaemia, n (%)	66 (66)
Diabetes, n (%)	28 (28)
Heart failure, n (%)	14 (14)
CKD, n (%)	29 (29)
Dialysis, n (%)	3 (3)
COPD, n (%)	16 (16)
Prior stroke/TIA, n (%)	9 (9)
Prior PCI, n (%)	19 (19)
Prior AMI, n (%)	8 (8)
Prior CABG, n (%)	2 (2)
Prior valvular surgery, n (%)	0 (0)
Type of prosthesis
CoreValve, n (%)	1 (1)
CoreValve Evolut R, n (%)	69 (69)
CoreValve Evolut Pro, n (%)	1 (1)
SAPIEN 3, n (%)	28 (28)
Portico, n (%)	1 (1)
Prosthesis Dimension
23 mm, n (%)	18 (18)
25 mm, n (%)	1 (1)
26 mm, n (%)	39 (39)
28 mm, n (%)	1 (1)
29 mm, n (%)	28 (28)
34 mm, n (%)	6 (6)

AMI, acute myocardial infarction; CABG, coronary artery bypass graft; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; PCI, percutaneous coronary intervention; TIA, transient ischaemic attack.

Reproducibility

Measurement of LA strain showed a good reproducibility. Mean interobserver variation for LAS was 0.28±0.65, with an intraclass coefficient of correlation of 0.97 (95% CI 0.93 to 0.99; p<0.001) and a correlation coefficient of 0.98 (p<0.001).

Post-procedural results

TAVR was performed with either the balloon expandable EDWARDS Sapien 3 (n=28) or the self-expandable CoreValve (n=1), CoreValve Evolut R (n=69), CoreValve Evolut Pro (n=1) or Portico valve (n=1). A procedural success of TAVR was reached in all the included patients. No fatal periprocedural complications occurred in any of the study patients. Fifty-seven patients (57%) had post-TAVR mild AR, whereas six patients (6%) had mild-to-moderate post-TAVR AR. Finally, 21% of patients had conduction disturbances requiring post procedural pacemaker implantation.

The mean post-TAVR transvalvular aortic gradient was 9.7±4.8 mm Hg. No significant change in LVEF was found after TAVR to 53.4%±8.8% (p=0.125). LAVi was non-significantly reduced after TAVR to 37.2±14.5 mL/m2 (p=0.112). LAS was slightly improved after TAVR, although this difference was not statistically significant (LAS post-TAVR 15.8%±7.2%, p=0.649).

Impact of LA function on clinical events

During a median follow-up of 31 months, 35 patients (35%) met the combined clinical endpoint of cardiovascular death or hospitalisation for heart failure. Secondary endpoints are reported in table 4.

Table 4

Secondary endpoints

	All patients	High ΔLAS	Low ΔLAS	Significance (p value)
All-cause death	11	2	9	0.043
Myocardial infarction	0	0	0	–
Stroke/transient ischaemic attack	3	0	3	0.089

LAS, left atrial strain.

A lower ΔLAS was significantly associated with a higher incidence of the combined clinical endpoint (HR=0.76 (0.67–0.86); p<0.001) (figure 2). No significant difference was found for LVEF, E/E’, PASP, LAVi pre-TAVR (table 1, figure 2). A multivariate analysis was then run including ΔLAS, EuroSCORE II and LVEF. Results of the multivariate logistic regression analysis displayed in figure 3 showed that ΔLAS (HR=0.80, p<0.001) was an independent predictor of the combined endpoint.

Figure 2

Left atrial parameters according to patients’ outcome post-TAVR. LAS, left atrial strain; LAVi, left atrial volume index; TAVR, transcatheter aortic value replacement.

Table 1

Clinical characteristics of the study population

	All patients(n=100)	EVENTS(n=35)	NO EVENTS(n=65)	Significance(p value)
Age (years)	81.2±5.3	82±5.4	80.7±5.3	0.244
Female, n (%)	52 (52)	16 (46)	36 (55)	0.170
Weight (kg)	70.9±13.4	72.1±13.1	70.2±13.5	0.505
Height (cm)	161.1±7.7	162.7±8	160.1±7.4	0.110
BSA (m2)	1.78±0.19	1.8±0.19	1.76±0.18	0.329
BMI (kg/m2)	27.3±4.7	27.2±4.4	27.4±4.9	0.854
TAPSE pre-TAVR (mm)	22±2.6	22.4±2.6	21.7±2.5	0.285
AVA baseline (cm2)	0.75±0.15	0.74±0.12	0.76±0.17	0.498
AV mean gradient pre-TAVR (mm Hg)	47.9±13.4	47.8±12.8	48.1±13.9	0.920
AV peak gradient pre-TAVR (mm Hg)	74.4±18.5	74.7±18.5	74.3±18.6	0.912
LVEF pre-TAVR (%)	53.7±9.1	54.0±9.2	53.6±9.1	0.848
LVEDD pre-TAVR (mm)	50.2±6.2	49.9±6	50.4±6.3	0.746
LVESD pre-TAVR (mm)	33.8±7.2	33.2±5.7	34.1±8	0.610
IVSd pre-TAVR (mm)	12.9±1.6	12.9±1.7	12.9±1.6	0.996
LAVi pre-TAVR (mL/m2)	48.1±13.8	48.5±14.1	47.9±13.8	0.865
Aortic regurgitation pre-TAVR, n (%)				0.066
None	18 (18)	5 (14)	13 (20)	–
Mild	48 (48)	20 (57)	28 (43)	–
Mild-to-moderate	34 (34)	10 (29)	24 (37)	–
PASP (mm Hg)	39±11.1	38.5±10.4	39.3±11.6	0.793
E/A	0.72±0.3	0.71±0.2	0.72±0.4	0.923
average E/E‘	13.5±3.3	12.9±2.6	13.9±3.5	0.234
EuroSCORE II (%)	6.8±4.7	7.1±4.6	6.6±4.8	0.644
Creatinine (mg/dL)	1.2±0.9	1.1±0.5	1.3±1	0.317
GFR (mL/min)	54.9±21.7	58.1±24.1	53±20.1	0.279
Platelets	206±60.2	196.4±55.8	212.3±62.7	0.225
AV mean gradient post-TAVR (mm Hg)	9.7±4.8	8.6±3.8	10.4±5.3	0.088
LAVi post-TAVR (mL/m2)	47.3±15.3	50.4±17.4	43.8±12.2	0.281
LVEF post-TAVR (%)	53.4±8.8	53.5±8.2	53.4±9.3	0.983
Average E/E‘ post-TAVR	12.2±2.6	12.4±2.7	12±2.5	0.731
Aortic regurgitation post-TAVR, n (%)				0.962
None	37 (37)	12 (34)	25 (38)	–
Mild	57 (57)	21 (60)	36 (55)	–
Mild-to-moderate	6 (6)	2 (6)	4 (6)	–

AV, aortic valve; AVA, aortic valve area; BMI, body mass index; BSA, body surface area; E/A, early-to-late diastolic flow ratio; E/E’, E-to-mean E’ ratio; GFR, glomerular filtration rate; IVSd, interventricular septal diameter diastolic; LAVi, left atrial volume index; LVEDD, left ventricular end-diastolic diameter; LVEF, left ventricular ejection fraction; LVESD, left ventricular end-systolic diameter; PASP, pulmonary artery systolic pressure; TAPSE, tricuspid annular plane excursion; TAVR, transcatheter aortic valve replacement.

Figure 3

Multivariate logistic regression analysis showing that ΔLAS (HR=0.80, p<0.001) was an independent predictor of the main clinical endpoint. LAS, left atrial strain; LVEF, left ventricular ejection fraction.

At Kaplan-Maier analysis (figure 4), stratification of the study population based on ΔLAS showed that those with a ΔLAS above its median value had a significantly better event-free survival compared with those below the median (p<0.001).

Figure 4

Kaplan-Meier curve displaying the significant difference of event-free survival between patients with a ΔLAS above its median value compared with those below the median (p<0.001). LAS, left atrial strain.

Patients presented with low-flow low-gradient AS had lower baseline and post-TAVR LA strain, and lower ΔLAS by comparison to the remaining patients with classical high-gradient normal flow AS (table 4). However, the presence of low-flow low-gradient AS was not associated with a higher incidence of adverse events during the follow-up (p=0.727).

Predictors of reduction of LA peak systolic strain after TAVR

We explored the predictors of LA peak systolic strain after TAVR amidst clinical, baseline and relative changes of echocardiographic parameters. Multivariate regression analysis identified larger pre-procedural left ventricular end-systolic diameter (LVESD) (coeff β=−0.357, p=0.009) and female gender (coeff β=0.350, p=0.007) as independent predictors of a lower ΔLAS after TAVR.

Discussion

To the best of our knowledge, this is the first study demonstrating that post-procedural decrease in LA reservoir function, assessed by means of the peak systolic ΔLAS, can predict adverse events (composite endpoint of cardiovascular-mortality or heart failure hospitalisation) in a long-term follow-up of patients with AS undergoing TAVR.

LA volume has been recently employed as a diagnostic and prognostic tool in cardiovascular disease, including AS.2–6 Recent reports13 18 demonstrated LA volume and LA function do not progress side-by-side, because usually LA dysfunction precedes LA dilatation. It is widely acknowledged7 8 13 that LA function has three components: reservoir, conduit and booster pump. The reservoir function coincides with the LV systole; the conduit function derives from the blood passage from the LA to the LV in early diastole; and then, the booster pump function coming in late diastolic phase, corresponds to the LA contraction. The LA strain, specifically the peak positive longitudinal LA strain at end-systole assessed via 2D STE, which expresses the LA reservoir function, is a promising tool to evaluate LA function with incremental clinical value over LA volume.7–14 Interestingly, LA reservoir and conduit function are related to LV filling pressures and they are associated with LA fibrosis and remodelling in patients with cardiovascular disease, including severe mitral regurgitation undergoing surgery.14 28–31 Impairment of diastolic function, as a consequence of AS and of increased LV filling pressures, has already been described.18 Recent studies have shown LA peak systolic strain is impaired in patients with AS compared with healthy controls.18 Moreover, others19 21 demonstrated that LA peak systolic strain was an independent predictor of outcome in severe AS. Successful removal of LV pressure afterload (as after TAVR) has been revealed to normalise LA size,32 and patients who fail to do so remain threatened by recurrent adverse event.32 A short-term improvement in reservoir LA function following TAVR, assessed by 2D STE, has been described in recent reports.20 In this context, our results confirm and extent previous literature also demonstrating that the lack of improvement in reservoir LA function following TAVR, measured by means of the ΔLAS, is associated with worse outcome in a long-term follow-up. In line with previous reports, our findings did show that ΔLAVi was numerically higher in patients with events as compared with those who did not develop any clinical complications. However, this association was not statistically significant. This suggests that ΔLAS is a more sensitive prognostic marker than ΔLAVi, particularly for patients being at an earlier pathophysiological stage of the disease, as those enrolled in our study. In fact, it has been previously demonstrated that LAS has a higher sensitivity to detect earlier LA dysfunction by comparison to LA volume.2–6 13 18

On the contrary, we found an association between the post-TAVI recovery/impairment of LA function, in the form of ΔLAS, and a pre-existing larger LVESD and the presence of a male gender. Therefore, the lack of functional improvement might be related at least in part to the LVESD before procedure and more frequent in male patients with AS than females. The latter result suggests that the well-known gender differences, including the degree of concentric remodelling, of diastolic dysfunction and of vascular stiffness, might exert a sensible impact on the response to treatment.33 34

Our results suggest that the short-term increase of ΔLAS after TAVR may be useful to identify a category of patients at higher risk of cardiovascular mortality and hospital readmission as the result of recurrent heart failure. In these patients, a more diligent clinical control and a more aggressive medical therapy may be advantageous to prevent adverse clinical events.

Limitations

This is a single centre study. However, changes observed in our relatively small cohort are consistent, and support our data interpretation. Poor acoustic windows may prevent the precise characterisation of LA myocardial deformation and lead to potential mistakes in epicardial/endocardial border tracing. However, a careful endocardial delineation of LA myocardial segments, especially if performed by an experienced echocardiographer, and the exclusion from the study analysis of patients with poor image resolution, allow acquiring reproducible and reliable data.

Conclusions

This study demonstrated an improvement in LAS after TAVR and suggests it might be used as a prognostic marker. In fact, a lower reduction in ΔLAS in patients after TAVR was an independent predictor of the composite endpoint of cardiovascular death and hospitalisation for heart failure. Larger studies are required to confirm the predictive power of ΔLAS for patients’ risk stratification after TAVR.